Harpoon Therapeutics Inc
Harpoon Therapeutics Inc
HARP

Harpoon Therapeutics Inc (HARP)

$1.917.28%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.9
Day's Range
$2.0
$1.73
52-Week Range
$14.21
1 month return0.0%
3 month return58.8%
1 year return84.89%
5 year return84.74%

Company Information

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor.
OrganizationHarpoon Therapeutics Inc
Employees78
CEOGerald McMahon
IndustryBiotechnology

Analyst Recommendation

based on 15 analysts ratings

Buy
86%
Buy
13%
Hold
0%
Sell

Based on 15 Wall street analysts offering stock ratings for Harpoon Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 1330.89%

Current

$1.91

Target

$27.33

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
13
13
14
Hold
2
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
78.1M
Book Value
1.77
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-3.62
Wall Street Target Price
14.5

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
3.3
Price/Book (mrq)
1.57
Enterprise Value
-31607191
Enterprise Value/Revenue
0.59
Enterprise Value/Ebitda
0.49

Technicals

Beta
1.1
50 Day MA
4.28
200 Day MA
6.79

Institutional Holdings

MPM Oncology Impact Management LP

9.66%

New Leaf Venture Partners, L.L.C.

9.54%

Mpm Asset Management, LLC

9.46%

Orbimed Advisors, LLC

9.19%

BlackRock Inc

5.18%

Vanguard Group Inc

3.89%

Discover more

Frequently Asked Questions

What is Harpoon Therapeutics Inc share price today?

Can Indians buy Harpoon Therapeutics Inc shares?

How can I buy Harpoon Therapeutics Inc shares from India?

Can Fractional shares of Harpoon Therapeutics Inc be purchased?

What are the documents required to start investing in Harpoon Therapeutics Inc stocks?

What are today’s High and Low prices of Harpoon Therapeutics Inc?

What are today’s traded volumes of Harpoon Therapeutics Inc?

What is today’s market capitalisation of Harpoon Therapeutics Inc?

What is the 52 Week High and Low Range of Harpoon Therapeutics Inc?

How much percentage Harpoon Therapeutics Inc is down from its 52 Week High?

How much percentage Harpoon Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Harpoon Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Harpoon Therapeutics Inc?